News

CN Bio Innovations announces deal with sixth pharmaceutical collaborator in 2015 and features in The Economist

CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is featured prominently in an article in the 13 June 2015 edition of The Economist. Simultaneous with the publication, CN Bio is pleased to announce that it has embarked on a joint research collaboration with a sixth pharmaceutical company since March 2015. The research will be based on CN Bio’s Quantum-B® model of Hepatitis B infection and leverage CN Bio’s expertise in cell culture and disease modelling.

READ MORE

CN Bio Innovations announces research collaboration with Alnylam

CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with Alnylam Pharmaceuticals. Research relevant to the advancement of Alnylam’s RNAi therapeutics will be performed using CN Bio’s human liver-on-a-chip platform, LiverChip.

READ MORE

CN Bio Innovations announces LiverChip research study with leading pharmaceutical company

CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research study with a fourth pharmaceutical company.

The program will take advantage of CN Bio’s human liver-on-a-chip platform, LiverChip, to study targets implicated in liver disease.

READ MORE

CN Bio Innovations announces Hepatitis B research collaboration with leading pharmaceutical company

Welwyn Garden City, UK, 21st April 2015: CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with a third (undisclosed) pharmaceutical company. The research, which will take advantage of CN Bio’s full viral lifecycle… Read more »

READ MORE

CN Bio announces research collaboration with antisense discovery pioneers Isis Pharmaceuticals

CN Bio Innovations, an expert in developing human biomimetic platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with RNA based drug discovery and development company Isis Pharmaceuticals Inc. Research relevant to Isis’s innovative RNA targeting, antisense oligonucleotides will be performed at CN… Read more »

READ MORE

CN Bio announces opening of new Biosafety Level 3 facility

CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, announced today the opening of a new facility, including state-of-the-art Biosafety level 3 (BSL-3) laboratories, in Welwyn Garden City, UK.  The BSL-3 laboratories will be dedicated to research, development and drug discovery alliance programmes… Read more »

READ MORE

NIH Director highlights LiverChip in Compton Lecture

Dr Francis S. Collins, Director of the US National Institutes of Health (NIH), highlighted LiverChip during the 2014 Karl Taylor Compton Lecture on October 28 at the Massachusetts Institute of Technology. In his lecture entitled “Exceptional Opportunities in Biomedical Research” Collins featured work by MIT Professor Linda Griffith, S.E.T.I. Professor of Biological and Mechanical Engineering… Read more »

READ MORE

TSB Funds New Research by CN Bio into Fatty Liver Disease

CN Bio Innovations (CN Bio) announced today the receipt of a 12 months funding award from the UK’s Technology Strategy Board (TSB) for the development of human in vitro models of Non-Alcoholic Fatty Liver Disease (NAFLD). CN Bio will partner on the award with UK-based CRO Xenogesis Ltd., which specialises in preclinical DMPK, quantitative bioanalysis… Read more »

READ MORE

Imperial College London to present first public HBV data from CN Bio in vitro liver model

CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, has announced that data from its research collaboration with Imperial College London, where the team are analysing a novel human, full-viral-lifecycle model of Hepatitis B, will be the subject of oral and poster presentations… Read more »

READ MORE

CN Bio Innovations marks World Hepatitis Day by signing research agreement with Imperial College London

Collaboration will develop and further validate CN Bio’s in vitro model of Hepatitis B liver infection Oxford, UK, 28 July 2014: CN Bio Innovations Ltd (CN Bio), an expert in developing leading edge human biomimetic platforms to test and develop therapeutics for serious diseases, announced today that it has signed a research agreement with Imperial… Read more »

READ MORE

Promotion of Dr David Hughes to the role of Chief Technology Officer

Dr David Hughes has been promoted to the role of Chief Technology Officer, effective immediately. In his new role, he will take responsibility for overseeing management of all technical projects and alliances with CN Bio partners. He will also continue to manage the internal scientific and engineering teams. Dr Hughes joined the Company in 2010… Read more »

READ MORE

CN Bio appoints Professor Mark Thursz as Scientific Advisor

CN Bio Innovations (CN Bio) today announced the appointment of Professor Mark Thursz as a scientific advisor to the company. “Mark has considerable experience and a deep knowledge of clinical hepatology and related non-clinical research and I believe that CN Bio will benefit from having access to Mark’s expertise as we continue to develop and… Read more »

READ MORE